Filtering by
- All Subjects: Senior Living
- All Subjects: Cystic Fibrosis, Modulator Therapies
- Creators: Anand, Rohan
- Creators: Dicke, George
- Creators: Milovanovic, Jelena
- Creators: Stephens, Corey Christopher
- Creators: Tang, Julie
Through research, interviews, and analysis, our paper provides the local community with a resource that offers a comprehensive collection of insight into the Mirabella at ASU Life Plan Community and the projected impact it will have on the City of Tempe and Arizona State University.
Through research, interviews, and analysis, our paper provides the local community with a resource that offers a comprehensive collection of insight into the Mirabella at ASU Life Plan Community and the projected impact it will have on the City of Tempe and Arizona State University.
For years, patients with Cystic Fibrosis (CF) were able to only treat the symptoms of the disease, but advancements over the last decade have made it possible to partially correct the genetic mutation which causes the disease. Treatment for this disease has long been complex due to the number of organs affected by the mutation, but these new modulator therapies add another level of complexity due to the large yearly cost of $300,000. While approvals for the drugs are reaching more age groups in many countries, ease of access still varies due to the reimbursement deals or prescription coverage available in each country.